Skip to main content
Figure 3 | Cardiovascular Diabetology

Figure 3

From: CNX-012-570, a direct AMPK activator provides strong glycemic and lipid control along with significant reduction in body weight; studies from both diet-induced obese mice and db/db mice models

Figure 3

CNX-012-570 reduces blood glucose, glycerol and FFA: (A & D) Fasting Glucose levels were monitored weekly in both DIO and db/db mice respectively. At the end of treatment period, Fasting Serum FFA (B) and glycerol levels (C) were measured in DIO mice. (E) HbA1c levels in db/db mice at week 6. Clear bar-lean control, black bar-HFD or db/db control, grey bar-CNX-012-570 treatment (3 and 2.5 mg/kg, orally once a day in DIO and db/db mouse respectively). All the values are expressed as Mean ± SEM. Statistical comparison between control and treatment group was conducted by One-way ANOVA followed by Dunnett’s test (*P < 0.05, ** P < 0.01 and *** P < 0.001).

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840